Next Article in Journal
Epigenetics of Urological Cancers
Next Article in Special Issue
Curcumin Mitigates Immune-Induced Epithelial Barrier Dysfunction by Campylobacter jejuni
Previous Article in Journal
Structure and Dynamics of Mono- vs. Doubly Lipidated Rab5 in Membranes
Previous Article in Special Issue
Detailed Clinical Features of Deafness Caused by a Claudin-14 Variant
Open AccessArticle

Use of Modified Clostridium perfringens Enterotoxin Fragments for Claudin Targeting in Liver and Skin Cells

1
Charité-Universitätsmedizin Berlin, Institute of Clinical Physiology, Hindenburgdamm 30, 12203 Berlin, Germany
2
Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Straße 10, 13125 Berlin, Germany
3
Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK
4
Department of Dermatology and Venerology, University Hospital Hamburg Eppendorf, 20246 Hamburg, Germany
5
Oxford Centre for Gene Function, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX3 7DQ, UK
*
Author to whom correspondence should be addressed.
Current Address: London Institute of Medical Sciences, Biological Mass Spectrometry and Proteomics Facility, London W12 0NN, UK.
Int. J. Mol. Sci. 2019, 20(19), 4774; https://doi.org/10.3390/ijms20194774
Received: 17 August 2019 / Revised: 11 September 2019 / Accepted: 22 September 2019 / Published: 26 September 2019
(This article belongs to the Special Issue The Tight Junction and Its Proteins: More Than Just a Barrier)
Claudins regulate paracellular permeability in different tissues. The claudin-binding domain of Clostridium perfringens enterotoxin (cCPE) is a known modulator of a claudin subset. However, it does not efficiently bind to claudin-1 (Cldn1). Cldn1 is a pharmacological target since it is (i) an essential co-receptor for hepatitis C virus (HCV) infections and (ii) a key element of the epidermal barrier limiting drug delivery. In this study, we investigated the potential of a Cldn1-binding cCPE mutant (i) to inhibit HCV entry into hepatocytes and (ii) to open the epidermal barrier. Inhibition of HCV infection by blocking of Cldn1 with cCPE variants was analyzed in the Huh7.5 hepatoma cell line. A model of reconstructed human epidermis was used to investigate modulation of the epidermal barrier by cCPE variants. In contrast to cCPEwt, the Cldn1-binding cCPE-S305P/S307R/S313H inhibited infection of Huh7.5 cells with HCV in a dose-dependent manner. In addition, TJ modulation by cCPE variant-mediated targeting of Cldn1 and Cldn4 opened the epidermal barrier in reconstructed human epidermis. cCPE variants are potent claudin modulators. They can be applied for mechanistic in vitro studies and might also be used as biologics for therapeutic claudin targeting including HCV treatment (host-targeting antivirals) and improvement of drug delivery. View Full-Text
Keywords: Clostridium perfringens enterotoxin; claudin-1; Hepatitis C Virus; viral entry; epidermal barrier; reconstructed human epidermis; claudin targeting Clostridium perfringens enterotoxin; claudin-1; Hepatitis C Virus; viral entry; epidermal barrier; reconstructed human epidermis; claudin targeting
Show Figures

Figure 1

MDPI and ACS Style

Beier, L.-S.; Rossa, J.; Woodhouse, S.; Bergmann, S.; Kramer, H.B.; Protze, J.; Eichner, M.; Piontek, A.; Vidal-y-Sy, S.; Brandner, J.M.; Krause, G.; Zitzmann, N.; Piontek, J. Use of Modified Clostridium perfringens Enterotoxin Fragments for Claudin Targeting in Liver and Skin Cells. Int. J. Mol. Sci. 2019, 20, 4774.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop